Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  daclizumab
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-14 of 14 for your search:
Start Over
Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: CHOP-Z, NCT01418430
Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000269672, DFCI-99279, RPCI-DS-0218, ROCHE-RPCI-DS-0218, NCT00053976
Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000064351, BIDMC-92020534, NEDH-92020534, BIDMC-FDR001054, NCI-H95-0732, NCT00002681
Phase I/II Pilot Study of Anti-Tac Antibody Immunotherapy in Adults with Tac-Positive T-Cell Leukemia/Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-83-C-23, NCI-T84-0153N
Phase I/II Preliminary Feasibility Study of Immunotherapy with Pseudomonas Conjugated Anti-Tac Antibody for Adult T-Cell Leukemia/Lymphoma (Summary Last Modified 08/89)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-85-C-91, NCI-T85-0147N, T85-0147
Anti-Tac for Treatment of Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 10 and over
Sponsor: NCI
Protocol IDs: 000030, 00-C-0030, NCI-00-C-0030, NCT00020020, NCT00001941
Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000068212, MSGCC-0012, NCI-V00-1624, NCT00006350
Phase II Study of Yttrium-90-Labeled Humanized Anti-Tac MOAB in Patients with Tac-Expressing Adult T-Cell Leukemia/Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-93-C-0066F
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02580, UCCRC-10-324-B, CDR0000696233, 10-324-B, 8445, P30CA014599, N01CM00071, NCT01307618
Phase I Study of Single Intravenous Doses of Humanized Anti-Tac (Ro 24-7375) in Patients with Tac-Bearing Malignancies (Summary Last Modified 06/1999)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-92-C-0046, NCI-T91-0276N, T91-0276
Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: Pro00000947, R21CA132891, CDR0000579573, DUMC-PRO00000947, DUMC-SPORE II 2003 CMV Grant, NCT00626015
Multipeptide Vaccine for Advanced Breast Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 08107, NCT00573495
Start Over